Format

Send to

Choose Destination
Diabetes Res Clin Pract. 2018 May;139:323-330. doi: 10.1016/j.diabres.2018.03.011. Epub 2018 Mar 9.

Impact of cancer diagnosis on persistence of oral antidiabetic drugs.

Author information

1
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France; CHU de Bordeaux, Pôle de santé publique, Service de pharmacologie médicale, F-33000 Bordeaux, France. Electronic address: louis.letinier@u-bordeaux.fr.
2
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France.
3
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France; CHU de Bordeaux, Pôle de santé publique, Service de pharmacologie médicale, F-33000 Bordeaux, France.

Abstract

AIMS:

The purpose of this study was to determine the effects of cancer occurrence on persistence of oral antidiabetic drugs (OAD) in France.

METHODS:

A retrospective cohort including incident OAD users between 2006 and 2011 was set up using a permanent sample of health insurance beneficiaries (Echantillon Généraliste de Bénéficiaires, EGB). A Cox model was used to assess the association between cancer occurrence and OAD persistence. Non-persistence was defined as a gap in OAD treatment coverage between the end of a given prescription and a new one greater than or equal to 90 days. Cancer occurrence was studied as a time-dependent variable.

RESULTS:

The study included 13,943 OAD users. Median follow-up was 760 days. After adjustment for age, sex, first OAD used, type of prescriber and polypharmacy, non-persistence risk was higher after a diagnosis of cancer: (HR: 1.93 and IC 95% 1.69; 2.21). Subgroup analyses according to cancer localization found a higher risk of non-persistence for lung cancer (HR: 2.66 and IC 95% 1.68; 4.23) and colorectal cancer (HR: 2.02 and IC 95% 1.40; 2.91).

CONCLUSIONS:

Our findings indicate there is an association between cancer diagnosis and OAD non-persistence. Additional studies of this type would be useful to evaluate the association between cancer diagnosis and persistence of treatment of other chronic diseases.

KEYWORDS:

Cancer survivors; Medication compliance; Observational study; Patient education; Type 2 diabetes

PMID:
29526679
DOI:
10.1016/j.diabres.2018.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center